Airway hyperresponsiveness in asthma: not just a matter of airway inflammation

Vito Brusasco, Emanuele Crimi, Riccardo Pellegrino

According to the most recent definition, bronchial asthma is a chronic inflammatory disorder of the airways associated with reversible airway obstruction and increased airway responsiveness to a variety of stimuli. An intuitive inference from this definition is that a causal relationship may exist between airway inflammation and airway hyperresponsiveness. Along this line of reasoning, most of the research in the last two decades in this field was aimed at identifying inflammatory cell products possibly responsible for the pathogenesis of bronchial asthma and airway hyperresponsiveness. However, the common observation that the asthmatic airways are equally hyperresponsive to a variety of different stimuli does challenge the idea that a single inflammatory cell or mediator may be central to the pathogenesis of asthma and airway hyperresponsiveness and focuses on the importance of an altered mechanical response of the target organ. This view has been recently corroborated by the finding that airway responsiveness of normal individuals may become similar to that of asthmatics by simply changing the pattern of breathing during the bronchial challenge. It is therefore legitimate to wonder how much of airway hyperresponsiveness is due to inflammation or to inherent predisposing factors.

The aims of the present review are to show that airway narrowing in asthma is the ultimate result of an interaction between complex and multiple mechanisms not necessarily and uniquely related to airway inflammation, and to revisit the evidence on which the theorem “airway inflammation equal to airway hyperresponsiveness” has been constructed.

Mechanisms of airway narrowing in asthma

Airway calibre in vivo is the result of a delicate balance between the force generated by the airway smooth muscle (ASM) and a number of opposing factors. The latter are mainly represented by autonomic mechanisms that tend to limit the ASM tone and by mechanical forces that oppose ASM shortening.

AIRWAY SMOOTH MUSCLE (ASM)

Although it is widely accepted that ASM contraction is a major cause for airway obstruction in asthma, there is uncertainty as to whether abnormalities of ASM play any part in the pathogenesis of airway hyperresponsiveness. In terms of force-length characteristics, the asthmatic ASM does not behave differently from the normal ASM. These data lend support to a purely immunological view of bronchial asthma in which the ASM cell is regarded as a normal effector of response to abnormal inflammatory stimuli. Nevertheless, the smooth muscle of asthmatic airways may be able to generate greater force than normal because of hypertrophy and hyperplasia, thus causing excessive airway narrowing. Although the thickness of the ASM in the airway wall of asthmatic patients might have been overestimated and there is no proof that an increased mass of smooth muscle is associated with an increased force generation capacity, the possibility that an increased contractile force developed by ASM might contribute to airway hyperresponsiveness in asthma cannot be ruled out.

Recent work has suggested that normal and asthmatic ASM may differ in terms of length shortening characteristics. The capacity and the velocity of shortening are increased after passive sensitisation of ASM. The increase of shortening velocity is due to an increase in the amount and the activity of the myosin light chain kinase and increased phosphorylation of the 20 kD regulatory unit with increased cross-bridge cycling rate. Albeit small, the difference in shortening velocity between asthmatic and normal ASM may be relevant to the generation and maintenance of force. Under normal conditions stretching causes a transient reduction in ASM tone. This is considered an important mechanism for preventing excessive airway narrowing (see below) but it may be less efficient if the velocity of shortening is increased.

Moreover, sensitised ASM may develop a myogenic contractile response to stretching. This response, which is believed to be a consequence of conversion from multi-unit to single-unit ASM, has been invoked to explain the sustained bronchoconstriction that occurs in some asthmatics after taking one or more deep breaths.

MECHANICAL AND GEOMETRIC FACTORS

The mechanical properties of ASM are such that, if unimpeded, it may shorten to about 20–30% of its initial length when an appropriate stimulus is applied. In vivo, such a shortening would result in complete airway closure. In normal humans the maximal response to bronchoconstrictor stimuli is limited, which suggests that some mechanisms opposing ASM shortening are operative in vivo.

In vitro the shortening of ASM is considerably less when elastic loads are applied. Furthermore, human ASM shortens less than ASM from other species and this difference seems to be related to a greater amount of connective tissue present in human bronchi, which represents a parallel elastic load. It has been suggested that a decrease in the elastic load internal to ASM may contribute to greater ASM shortening in asthma.
Airway hyperresponsiveness in asthma

plates may also limit ASM shortening, thus preventing excessive airway narrowing, in rabbits, softening the tracheal cartilage by papain consistently increases airway resistance.

The most efficient force opposing ASM shortening in vivo is provided by the elastic recoil of the lung. When this is reduced, as in emphysema, the airways can become more narrow more easily. Although there is no consistent proof that lung elastic recoil is reduced in asthma, even small decrements of transpulmonary pressure near functional residual capacity may have a deleterious effect when the ASM contracts. In normal individuals the response to methacholine is greatly enhanced by breathing just 500 ml below FRC—that is, at a lung volume at which transpulmonary pressure is only a few cm H2O less.

The load imposed on the airways by the surrounding lung parenchyma changes during breathing. Due to their visco-plasto-elastic properties, both lung parenchyma and airways dissipate energy during breathing. For example, the force necessary to elongate the ASM in vitro is slightly but consistently greater than that necessary to bring it back to its original length. Such an energy dissipation becomes as much as 15 times greater when the ASM is contracted, depending on the frequency and amplitude of the length oscillations. Basically, energy dissipation implies less ASM force and, by inference, less bronchoconstriction. During inspiration the airways are stretched by the force of interdependence through which they are coupled with lung parenchyma. If this force is effectively applied to the external airway wall, then ASM shortening may be opposed. Increasing tidal volume therefore reduces the response to bronchoconstrictor stimuli. When a stretch volume therefore reduces the response to methacholine is greatly enhanced by breathing just 500 ml below FRC—that is, at a lung volume at which transpulmonary pressure is only a few cm H2O less.

The lack of protection from excessive airway narrowing observed in asthma can be, at least in part, reasonably attributed to airway inflammation or inflammatory remodelling of the airway walls.

It has been suggested that peri-bronchial oedema may attenuate the pulling effect of parenchymal attachments on airway walls, thus unloading the ASM and allowing more shortening for the same intensity of stimulus. The airway wall thickening that occurs in bronchial asthma due to oedema, cellular infiltration, and vascular engorgement may amplify the bronchoconstrictor response as it causes airway calibre to decrease more for a given ASM shortening. However, the effect of mucosal thickening on airway narrowing is complex. Airway mucosa folds when ASM shortens, a process that requires energy dissipation and hence may represent a load for the ASM. In addition, the subepithelial fibrosis characteristic of asthma makes the airway stiff, thus opposing ASM shortening.

On the other hand, the degree of airway narrowing is
Airway inflammation and airway hyperresponsiveness

The concept of asthma as an inflammatory disorder derives from necropsy studies on asthmatic subjects who died because of an asthma attack or other causes, and in vivo studies using bronchoalveolar lavage, induced sputum, and bronchial biopsy specimens in subjects with asthma of different severity, either at baseline or after exposure to allergens or occupational sensitizers.

The most prominent feature in necropsies of patients with fatal asthma is a marked thickening of airway walls. This is commonly associated with epithelial damage, thickening of basement membrane, marked increase of bronchial capillary bed, fluid exudation with oedema, goblet cell hyperplasia, ASM hyperplasia and hypertrophy, and intraluminal mucus and cellular debris causing complete or partial airway occlusion. The eosinophil is generally the dominating inflammatory cell in both fatal and non-fatal asthma, but neutrophils may prevail in cases of sudden onset fatal asthma. The airway walls of subjects with non-fatal asthma are also thicker than normal but to a lesser extent than those of subjects with fatal asthma.

Common findings in the biopsy specimens of asthmatic airways are epithelial shedding, collagen deposition below the basement membrane, increased numbers of eosinophils and mast cells in the mucosa. Eosinophils, mast cells and their products are also increased in the bronchoalveolar lavage fluid. In this scenario the recruitment and activation of Th2 cells seem to play a central role.

Airway inflammation as a cause of airway hyperresponsiveness: Pros

In asthmatic subjects inhalation of allergen or occupational sensitizers causes an inflammatory (mainly eosinophilic) response in the airways which is associated with an increase in airway hyperresponsiveness. In both healthy humans and animals exposure to ozone causes an inflammatory (mainly neutrophilic) response and airway hyperresponsiveness. A temporal relationship exists between the inflammatory events occurring in the airways and the increase in airway responsiveness after exposure to allergens. Both the influx of eosinophils and the increase in airway responsiveness precede the development of the late phase response. Airways hyperresponsiveness often first appears or worsens following a viral infection of the upper airways or vaccination with live influenza virus. The increase in airways responsiveness after rhinovirus infection is associated with an increase in the number of eosinophils in the sputum. Airways hyperresponsiveness in these models may be the result of an increased reflex bronchoconstriction via cholinergic and non-cholinergic excitatory neural pathways. Epithelial necrosis, reduced production of epithelial relaxing factors such as PGE_2 and neuropeptides, or loosening of tight junctions with overexpression of sensory nerve endings caused by viral replication are the putative underlying mechanisms. In animal models infection with parainfluenza 3 virus blocks the ability of β_2 adrenoceptor agonists to inhibit antigen-induced contraction of isolated ASM, reduces the activity of muscarinic M_2 autoreceptors, and increases the number and the releasability of bronchial mast cells. The last two effects have been found to be strictly associated with the development of sustained airways hyperresponsiveness. A virus induced overproduction of interferon gamma (IFNγ) from macrophages and lymphocytes has been indicated as the responsible mechanism.

Airway inflammation as a cause of airway hyperresponsiveness: Cons

Airway inflammation can be observed both in asthmatic and in atopic non-asthmatic subjects. In subjects with allergic rhinitis who have never experienced asthma symptoms both local and inhalational allergen challenge cause an eosinophilic inflammatory response which cannot be easily distinguished from that seen in asthmatic subjects, but the functional responses are different.

There is no evidence to suggest that neutrophils play a role in airway hyperresponsiveness in humans. In animal models airway neutrophilia induced by sulphur dioxide or endotoxin is associated with hyporesponsiveness rather than hyperresponsiveness.

The presence of high IgE levels in infancy seems to be a more important predisposing factor for the development of airway hyperresponsiveness than the occurrence of common viral infections in early life.

Epithelial damage after vaccination with live influenza virus occurs both in healthy and asthmatic subjects but airway hyperresponsiveness develops only in the latter, suggesting that individual related factors make an important difference.

The results of studies on the relationships between airway hyperresponsiveness and airway inflammation at baseline are largely inconsistent (table 1). In some instances weak correlations were found between one or more of the inflammatory markers (mainly eosinophils, T lymphocytes and epithelial shedding) and the degree of airway hyperresponsiveness. However, spurious correlations may have resulted from the inclusion of non-asthmatic controls in the regression analysis. Moreover, in an almost equal number of studies no significant correlations were found between airway inflammation and airway hyperresponsiveness. In particular, it was found that airway hyperresponsiveness...
Firstly, can airway hyperresponsiveness develop independent of airway inflammation—for example, as a consequence of inherited abnormalities of ASM contractility or autonomic regulation? This hypothesis cannot be ruled out even if the gaussian distribution of airway hyperresponsiveness in the general population and its partial reversibility after pharmacological treatments or allergen avoidance seem to suggest a major role for acquired rather than for inherited factors.

Secondly, is a specific type of inflammation responsible for airway hyperresponsiveness? At present the most appealing hypothesis is that airway hyperresponsiveness is the consequence of repeated episodes of airway inflammation in susceptible subjects. In this connection, allergic inflammation seems to play a major part as atopy with high serum IgE levels is associated with an increased risk of airway hyperresponsiveness in humans. In bronchial biopsy specimens of asthmatic subjects the Th2 phenotype has been found to be associated with airway hyperresponsiveness. Moreover, in some animal models exposure to the sensitising agent causes an inflammatory response characterised by Th2 lymphocyte activation, IL-5 and eosinophil activation, which is followed by the development of airway hyperresponsiveness. In a murine model, however, airway hyperresponsiveness was obtained even without eosinophil infiltration and was prevented by treatment with anti-IFN-γ antibodies, suggesting that eosinophil recruitment and airway responsiveness are differently regulated.

Thirdly, in which way may airway inflammation lead to the development of airway hyperresponsiveness? One possibility is that the release of mediators (histamine, leukotrienes, PAF, proteases) changes ASM contractility or autonomic regulation. Another possibility is that airway inflammation leads to airway remodelling through the release of chemokines and cytokines. Eotaxin, RANTES, MCP-3, MCP-4, IL-5 and IL-8 promote recruitment, activation and survival of inflammatory cells. IL-4, TGF-β, GM-CSF, TNF and IL-1β modify other aspects of airway biophysiology as antigen processing (Th1-Th2 switch), nitric oxide synthesis, β2 adrenoceptor function and the homeostasis of epithelial cells, fibroblasts, myofibroblasts, and also ASM cells. The former mechanism would be responsible for transient hyperresponsiveness upon exposure to triggers, the latter for sustained baseline hyperresponsiveness.

Fourthly, are there inherited factors that modulate the consequences of inflammation on airway structure? This possibility is suggested by epidemiological data indicating that a child with an allergic parent has an increased risk of developing the same allergic disease as affects the parent, whereas the risk of developing a different allergic disease is not significantly different from that for the general population.

Table 1 Studies in human subjects showing (+) and not showing (−) significant correlations between airway inflammation and airway hyperresponsiveness

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>BAL</th>
<th>BB</th>
<th>Sputum</th>
<th>Marker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kirby et al115</td>
<td>1987</td>
<td>+ Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Wardlaw et al116</td>
<td>1988</td>
<td>+ Eos, MBP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kelly et al117</td>
<td>1988</td>
<td>− Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Chan Yeung et al118</td>
<td>1988</td>
<td>− Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Piss et al119</td>
<td>1989</td>
<td>+ Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Jefferie et al120</td>
<td>1989</td>
<td>− Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Fergon et al121</td>
<td>1989</td>
<td>+ Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Gibson et al122</td>
<td>1989</td>
<td>− Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Djukanovic et al123</td>
<td>1990</td>
<td>− EG2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brunaceco et al124</td>
<td>1990</td>
<td>− Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Forese et al125</td>
<td>1990</td>
<td>− Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Adelroth et al126</td>
<td>1990</td>
<td>− Eos, ECP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bradley et al127</td>
<td>1991</td>
<td>+ EG2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Walker et al128</td>
<td>1991</td>
<td>+ Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Bentley et al129</td>
<td>1992</td>
<td>+ EG2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oilerenshaw et al130</td>
<td>1992</td>
<td>− Eos</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferguson et al131</td>
<td>1992</td>
<td>2 Eos, ECP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pin et al132</td>
<td>1993</td>
<td>+ Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Duddridge et al133</td>
<td>1994</td>
<td>− Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Inedale et al134</td>
<td>1994</td>
<td>− Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Woolley et al135</td>
<td>1996</td>
<td>+ EG2, Eos</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chetta et al136</td>
<td>1996</td>
<td>+ Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Kidney et al137</td>
<td>1996</td>
<td>− Eos</td>
<td></td>
<td></td>
<td>Eos</td>
</tr>
<tr>
<td>Pizzichini et al138</td>
<td>1996</td>
<td>+ Eos, MBP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forese et al139</td>
<td>1997</td>
<td>+ EG2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crimi et al140</td>
<td>1998</td>
<td>− Eos, Eos</td>
<td></td>
<td></td>
<td>Eos, ECP</td>
</tr>
</tbody>
</table>

BAL = bronchoalveolar lavage; BB = bronchial biopsy; Eos = number or percentage of eosinophils; ECP = eosinophil cationic protein; MBP = major basic protein; EG2 = cells stained with anti-ECP antibodies.


may be present even in the absence of demonstrable inflammatory cells in the airway lumen or mucosa, which suggests that the presence of inflammatory cells in the airways is not necessary to sustain airway hyperresponsiveness.

In lung transplant recipients airway hyperresponsiveness was reported without airway inflammation, suggesting that an altered neural control of ASM tone may play a major role in these subjects.

OPEN QUESTIONS

Owing to the lack of evidence that airway hyperresponsiveness and airway inflammation are closely related, there are several questions that must be answered before a causal relationship between airway inflammation and airway hyperresponsiveness in asthma can be established or rejected.

Figure 1 Hypothetical mechanisms and pathways of airway hyper-responsiveness.

Inherited factors

Environmental risk factors

Airway inflammation

ASM contractility

Airway remodelling

Lung to airway interdependence

Airway hyperresponsiveness

Firstly, can airway hyperresponsiveness develop independent of airway inflammation—for example, as a consequence of inherited abnormalities of ASM contractility or autonomic regulation? This hypothesis cannot be ruled out even if the gaussian distribution of airway hyperresponsiveness in the general population and its partial reversibility after pharmacological treatments or allergen avoidance seem to suggest a major role for acquired rather than for inherited factors.

Secondly, is a specific type of inflammation responsible for airway hyperresponsiveness? At present the most appealing hypothesis is that airway hyperresponsiveness is the consequence of repeated episodes of airway inflammation in susceptible subjects. In this connection, allergic inflammation seems to play a major part as atopy with high serum IgE levels is associated with an increased risk of airway hyperresponsiveness in humans. In bronchial biopsy specimens of asthmatic subjects the Th2 phenotype has been found to be associated with airway hyperresponsiveness. Moreover, in some animal models exposure to the sensitising agent causes an inflammatory response characterised by Th2 lymphocyte activation, IL-5 and eosinophil activation, which is followed by the development of airway hyperresponsiveness. In a murine model, however, airway hyperresponsiveness was obtained even without eosinophil infiltration and was prevented by treatment with anti-IFN-γ antibodies, suggesting that eosinophil recruitment and airway responsiveness are differently regulated.

Thirdly, in which way may airway inflammation lead to the development of airway hyperresponsiveness? One possibility is that the release of mediators (histamine, leukotrienes, PAF, proteases) changes ASM contractility or autonomic regulation. Another possibility is that airway inflammation leads to airway remodelling through the release of chemokines and cytokines. Eotaxin, RANTES, MCP-3, MCP-4, IL-5 and IL-8 promote recruitment, activation and survival of inflammatory cells. IL-4, TGF-β, GM-CSF, TNF and IL-1β modify other aspects of airway biophysiology as antigen processing (Th1-Th2 switch), nitric oxide synthesis, β2 adrenoceptor function and the homeostasis of epithelial cells, fibroblasts, myofibroblasts, and also ASM cells. The former mechanism would be responsible for transient hyperresponsiveness upon exposure to triggers, the latter for sustained baseline hyperresponsiveness.

Fourthly, are there inherited factors that modulate the consequences of inflammation on airway structure? This possibility is suggested by epidemiological data indicating that a child with an allergic parent has an increased risk of developing the same allergic disease as affects the parent, whereas the risk of developing a different allergic disease is not significantly different from that for the general population.

Firstly, can airway hyperresponsiveness develop independent of airway inflammation—for example, as a consequence of inherited abnormalities of ASM contractility or autonomic regulation? This hypothesis cannot be ruled out even if the gaussian distribution of airway hyperresponsiveness in the general population and its partial reversibility after pharmacological treatments or allergen avoidance seem to suggest a major role for acquired rather than for inherited factors.

Secondly, is a specific type of inflammation responsible for airway hyperresponsiveness? At present the most appealing hypothesis is that airway hyperresponsiveness is the consequence of repeated episodes of airway inflammation in susceptible subjects. In this connection, allergic inflammation seems to play a major part as atopy with high serum IgE levels is associated with an increased risk of airway hyperresponsiveness in humans. In bronchial biopsy specimens of asthmatic subjects the Th2 phenotype has been found to be associated with airway hyperresponsiveness. Moreover, in some animal models exposure to the sensitising agent causes an inflammatory response characterised by Th2 lymphocyte activation, IL-5 and eosinophil activation, which is followed by the development of airway hyperresponsiveness. In a murine model, however, airway hyperresponsiveness was obtained even without eosinophil infiltration and was prevented by treatment with anti-IFN-γ antibodies, suggesting that eosinophil recruitment and airway responsiveness are differently regulated.

Thirdly, in which way may airway inflammation lead to the development of airway hyperresponsiveness? One possibility is that the release of mediators (histamine, leukotrienes, PAF, proteases) changes ASM contractility or autonomic regulation. Another possibility is that airway inflammation leads to airway remodelling through the release of chemokines and cytokines. Eotaxin, RANTES, MCP-3, MCP-4, IL-5 and IL-8 promote recruitment, activation and survival of inflammatory cells. IL-4, TGF-β, GM-CSF, TNF and IL-1β modify other aspects of airway biophysiology as antigen processing (Th1-Th2 switch), nitric oxide synthesis, β2 adrenoceptor function and the homeostasis of epithelial cells, fibroblasts, myofibroblasts, and also ASM cells. The former mechanism would be responsible for transient hyperresponsiveness upon exposure to triggers, the latter for sustained baseline hyperresponsiveness.

Fourthly, are there inherited factors that modulate the consequences of inflammation on airway structure? This possibility is suggested by epidemiological data indicating that a child with an allergic parent has an increased risk of developing the same allergic disease as affects the parent, whereas the risk of developing a different allergic disease is not significantly different from that for the general population.
Conclusions

Airway inflammation and airway hyperresponsiveness, two major characteristics of bronchial asthma, are loosely related to each other. It seems that the presence of inflammatory cells in the airways is neither sufficient nor necessary for the development of airway hyperresponsiveness. This would imply that an altered response of the target organ is a prerequisite for airway hyperresponsiveness to develop. In this scenario, chronic airway inflammation is likely to play a key role as a stimulus for structural changes (airway wall remodelling, changes in airway to lung interdependence, changes in ASM contractility) affecting the organ response to acute stimuli (fig 1). A practical conclusion is that no inferences about airway hyperresponsiveness can be drawn from measurements of airway inflammation and vice versa.


Airway hyperresponsiveness in asthma


Airway hyperresponsiveness in asthma: not just a matter of airway inflammation

Vito Brusasco, Emanuele Crimi and Riccardo Pellegrino

Thorax 1998 53: 992-998
doi: 10.1136/thx.53.11.992

Updated information and services can be found at:
http://thorax.bmj.com/content/53/11/992

These include:

References
This article cites 113 articles, 13 of which you can access for free at:
http://thorax.bmj.com/content/53/11/992#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Asthma (1782)
- Inflammation (1020)
- Airway biology (1100)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/